Nuclear Imaging in Drug Discovery, Development, and Approval.
General Material Designation
[Book]
.PUBLICATION, DISTRIBUTION, ETC
Name of Publisher, Distributor, etc.
Birkhauser
Date of Publication, Distribution, etc.
2012
PHYSICAL DESCRIPTION
Specific Material Designation and Extent of Item
pages
CONTENTS NOTE
Text of Note
1. Nuclear Imaging in Drug Development-Introduction.- 2. Nuclear Medicine Physics, Instrumentation, and Data Processing in Pharmaceutical Research.- 3. Accelerators for Positron Emission Tomography.- 4. Chemistry of Tracers for Positron Emission Tomography.- 5. Single Photon, Gamma Emitting Radiotracers for Use in Imaging.- 6. The Design of Site-Directed Radiopharmaceuticals for Use in Drug Discovery.- 7. Applications of Autoradiography to Drug Discovery.- 8. Quantitative Whole Body Autoradiographic Microimaging for Pharmaceutical Research.- 9. Cerebral Metabolic Rates of 2-[18F]Fluoro-2-Deoxy-D-Glucose in the Presence of Ofloxacin A GABAA Receptor Antagonist.- 10. Positron Emission Tomography, Enzymes and Drug Research and Development.- 11. The Role of Positron Emission Tomography in Assessing and Monitoring Dopamine Active Drugs.- 12. Iodinated Dopamine D1 and D2 Receptor Imaging Agents for SPECT.- 13. Radiolabeled Atrial Natriuretic Peptide and Somatostatin for In Vivo Imaging of Receptors.- 14. Use of Radionuclides in Experimental Vascular Thrombosis.- 15. Application of Nuclear Imaging to Drug Delivery Evaluation and Development: A Review of Radiolabeled, Injectable, Colloidal Systems of Delivery.- 16. The Gastrointestinal Transit and Systemic Absorption of Diltiazem HCL from a Modified Release Dosage Form.- 17. The Potential Uses of Radiopharmaceuticals in the Pharmaceutical Industry.